Does alpha-fetoprotein contribute to the mortality and morbidity of human hepatocellular carcinoma? A commentary

Gerald J Mizejewski
Wadsworth Center, New York State Department of Health, Albany, NY, USA

Abstract: The fifth most common cancer worldwide is hepatocellular carcinoma (HCC), while being the third leading cause of global cancer-related deaths. Although HCC incidence is less frequent in North America, it is a common malignancy in Asia and Africa associated with a high rate of mortality and morbidity due to ineffective therapies against cancer growth, invasion, and metastasis. It is well established that serum alpha-fetoprotein (AFP) is the “gold standard” biomarker for liver cancer; however, less known are the biological activities of AFP regarding carcinogenesis, growth, proliferation, and metastasis. Clinicians are well aware that increasing AFP serum levels parallel disease progression of HCC patients, but many are less knowledgeable in the lethal growth-promoting properties of AFP as an autocrine stimulator of hepatoma cell proliferation. This commentary addresses the mortality and morbidity concerning AFP in the genesis, growth, progression, and spread of HCC and emphasizes the perilous consequences of AFP-supported growth in human liver cancer even after liver resection and transplantation. Thus, AFP is not just a biomarker for HCC but also an ardent promoter of liver cancer growth and progression.

Keywords: growth, metastasis, carcinogenesis, proliferation, cancer

Commentary

Alpha-fetoprotein (AFP) serum concentrations in adults, similar to fetal AFP, have long served as a biomarker for distress, dysfunction, and presence of abnormal growth and anatomical malformations. During pregnancy, AFP serum levels are indicators of fetal defects and chromosomal abnormalities, while in adults, elevated AFP levels designate the presence of liver cirrhosis, viral hepatitis, and hepatocellular carcinoma (HCC). Although less familiar in the clinic, a major physiological property of AFP is that of a growth factor that is advantageous for the fetus by promoting growth and cell proliferation. However, the same beneficial trait of AFP in adults is extremely deleterious and lethal when associated with cellular transformation, growth, proliferation, and metastasis of liver cancer. The objective of the present commentary is to communicate a call of alert to the biomedical community of just how hazardous the AFP growth factor effect can be to the well-being of liver cancer patients. Although most clinicians are well informed of the correlation of elevated AFP levels with increasing severity of disease (ie, cancer), recent discoveries in the AFP-to-cancer biological relationships have greatly increased our knowledge concerning potential health threats to HCC patients. These newly revealed AFP reports in vitro, in vivo, and in patients.
have encompassed carcinogenesis, growth, proliferation, invasion, and metastasis of human liver cancer.

**Hepatocarcinogenesis**

Recent developments in the last decade have provided increased insight into the physiological role of extracellular (secreted) and intracytoplasmic (cell bound) AFP forms involved in all aspects of the genesis and progression of HCC. At the onset of hepatocarcinogenesis, AFP is regulated early in the process of cell transformation of liver parenchymal cells into hepatoma cells; moreover, AFP contributes to various malignant cell behaviors. In hepatitis B (HB) virus-infected liver cells, AFP is known to mediate HBx protein activity during the induction of liver carcinogenesis. The AFP receptor signal pathway has also been reported to be a contributor to HBx-driven hepatocarcinogenesis. AFP was further found capable of blocking the expression of the retinoic acid receptor whose presence can interfere with Fn14 gene induction to promote apoptosis, angiogenesis, and proliferation of endothelial cells during the process of hepatocarcinogenesis. The Fn14 gene products are also known to be stimulators of hepatoma growth signal transduction pathways. Finally, AFP was found to activate AKT (protein kinase B) acting on mTOR in liver cells transfected with the HBx protein, thereby promoting malignant cell transformation via activation of PI3K together with mTOR.

**HCC growth and proliferation**

Regarding the growth of cancer cells, AFP has been well documented in promoting the growth and proliferation of HCC cells. Toward this end, AFP has been reported to upregulate in vitro the growth and progression of HCC cells by 120%–150%. In addition, AFP is known to influence growth via cell cycle progression by regulation of the G1- to S-phase transition stage. To further maintain cancer growth and progression, AFP promotes HCC-related angiogenesis of new blood vessels to supply nutrients to the tumor. AFP is also able to inhibit apoptosis of HCC cells, thus increasing cancer cell population numbers. AFP has also been known to shield HCC cells from tumor necrosis factor-induced cell death and to promote escape of tumor cells from lymphocyte cytotoxic cells via the caspase enzyme pathways. In this regard, AFP is capable of physically binding to caspase-3, but not caspase-8 or -9. In the enhancement of HCC cell proliferation, AFP can upregulate KRas, cyclic adenosine monophosphate, and protein kinase A and increase cytosolic Ca++ levels. Thus, AFP cooperates with both growth factors and transcription factors to promote HCC cell growth. In the regulation of PI3K/AKT activation, AFP is able to promote degradation of the p27 cell cycle inhibitor by means of ubiquitin ligases, thus advancing cell cycle progression. Finally, during the AFP interaction in retinoic acid receptor signaling pathways, the repression of GAAD153 (growth arrest and DNA damage-inducible protein-153) serves to enhance HCC growth.

**HCC invasion and metastasis**

AFP has recently been reported to play a crucial role in HCC cell metastasis and invasion. In that report, high serum levels of AFP were positively correlated with HCC intrahepatic invasion and extrahepatic lung node and lung metastasis. The investigators found that AFP promoted the expression of four metastasis-related proteins, including keratin-19, epithelial cell adhesion molecule, matrix metalloproteinases 2 and 9, and CXC chemokine receptor-4. The latter chemokine receptor plays a major chemoattractant role by directing cancer cells to home into specific organs, that is, lymph nodes, bone marrow, and lungs. In further studies, AFP was found in 60% of circulating tumor cells of HCC patients related proteins. Finally, AFP messenger RNA expression levels were higher in HCC metastasis patients than in sera of patients with hepatic trauma and dysfunction. Furthermore, AFP was reported to promote distant metastasis of HCC cells implanted in mouse xenograft models. Thus, AFP harbors a function to aid in HCC cell migration and invasion by several means, one of which is to stimulate expression of metastasis-related proteins. Finally, AFP messenger RNA expression was found in 60% of circulating tumor cells of HCC patients diagnosed with metastasis. It has become obvious that AFP is an active agent in HCC invasion and metastasis.

**HCC in liver resection and transplantation**

Liver resection in HCC patients is a potentially curative, low-cost medical procedure if performed soon after HCC diagnosis. In contrast, liver transplantation can include long waiting periods and higher surgical costs requiring patients who display preserved liver function. Although there are no established cutoff values for serum AFP levels following liver resection and transplantation, published reports indicate...
that the serum AFP clinical outcomes discussed earlier hold true to concept. Following liver resection, serum AFP levels >400 ng/mL signify a higher risk of microvascular invasion in liver tissue, HCC recurrence, and poor patient survival.25 In cases of liver transplantation after primary liver resection, serum AFP levels <200 ng/mL were associated with lower HCC recurrence and higher patient survival rates.26 As shown in this report, lower serum AFP levels favor increased patient survival times, while increased serum AFP levels reflect a detriment to patient health and well-being.

**Conclusion**

It is now evident that serum and cytoplasmic AFP are not just bystander agents but are active participants in all phases of transformation, growth, proliferation, and metastasis of the HCC malignant state. Thus, AFP is intrinsically involved in the overall process of cancer progression from carcinogenesis to metastasis. The earlier discussion demonstrates that AFP is a lethal compound involved in HCC cell apoptosis, shielding, lymphocyte escape, cell cycle progression, and signal transduction pathways. In many of the reports cited earlier,15–17 knockout of the AFP gene inhibited and repressed HCC tumor growth, while the transfection of the AFP gene into non-AFP hepatomas initiated HCC tumor genesis, growth, and progression. It is apparent that the absence of AFP from the tumor environment eliminates much of the tumor lethality and reduces HCC growth, while AFP presence adds to the lethality of tumor presence. Although AFP is known as the “gold standard” biomarker for HCC, it must be emphasized that AFP itself is a highly effective growth factor and not all clinicians may be aware of its immense potential for enhancing HCC growth. Indeed, it has recently been reported that AFP contains three epidermal growth factor motifs, one on each domain of the AFP polypeptide.27 Although AFP greatly contributes to fetal growth during pregnancy, full-length AFP can now be documented to play a lethal role in the growth and progression of HCC. In conclusion, it is of utmost importance that recombinant AFP should not be employed as a therapeutic agent to treat human disease (cancer, autoimmune disorders, etc). Since AFP is a “loose cannon” bristling with protein-to-protein interaction sites, it would be instead more prudent to use AFP-derived domain fragments and/or peptide segments for any type of therapy in humans. Hypothetically, the ultimate therapy for HCC should include 1) downregulation of the AFP gene, 2) use of microRNA and small interfering RNA against AFP, and/or 3) AFP vaccination against HCC.

**Disclosure**

The author reports no conflicts of interest in this work.

**References**